GT Biopharma Inc (GTBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2011 | 12-2010 | 09-2010 | 06-2010 | 03-2010 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1 | 54 | 181 | 571 | 840 |
| TOTAL | $96 | $137 | $259 | $610 | $840 |
| Non-Current Assets | |||||
| Intangibles | 41 | 48 | 70 | 77 | 84 |
| TOTAL | $41 | $48 | $70 | $77 | $84 |
| Total Assets | $137 | $185 | $329 | $687 | $924 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 1,823 | 1,959 | 1,564 | 1,677 | 1,871 |
| Accounts payable and accrued liabilities | 856 | 625 | 624 | 810 | 779 |
| Accrued Expenses | 3,283 | 1,853 | 1,716 | 1,586 | 1,505 |
| Other current liabilities | 984 | 1,012 | 1,081 | 1,450 | 3,153 |
| TOTAL | $7,161 | $5,654 | $5,190 | $5,778 | $7,543 |
| Non-Current Liabilities | |||||
| Long Term Debt | N/A | N/A | 404 | 404 | 496 |
| TOTAL | $N/A | $N/A | $404 | $404 | $496 |
| Total Liabilities | $7,161 | $5,654 | $5,594 | $6,182 | $8,039 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 191,245 | 162,681 | 144,672 | 118,510 | 105,015 |
| Common Shares | 170 | 149 | 144 | 119 | 80 |
| Retained earnings | -82,018 | -80,095 | -79,433 | -78,800 | -79,199 |
| Other shareholders' equity | 3 | 3 | 1 | 1 | 1 |
| TOTAL | $-7,024 | $-5,469 | $-5,265 | $-5,495 | $-7,115 |
| Total Liabilities And Equity | $137 | $185 | $329 | $687 | $924 |